TR199901855T2 - Flore edilmis 17alfa -alkil zincirli antigestajen etkili steroyidler. - Google Patents

Flore edilmis 17alfa -alkil zincirli antigestajen etkili steroyidler.

Info

Publication number
TR199901855T2
TR199901855T2 TR1999/01855T TR9901855T TR199901855T2 TR 199901855 T2 TR199901855 T2 TR 199901855T2 TR 1999/01855 T TR1999/01855 T TR 1999/01855T TR 9901855 T TR9901855 T TR 9901855T TR 199901855 T2 TR199901855 T2 TR 199901855T2
Authority
TR
Turkey
Prior art keywords
group
hydrogen atom
steroids
atom
formula
Prior art date
Application number
TR1999/01855T
Other languages
English (en)
Inventor
Schwede Wolfgang
Cleve Arwed
Klar Ulrich
Neef Gunter
Chwalisz Kristof
Schneider Martin
Fuhrmann Ulrike
Hess-Stumpp Holger
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of TR199901855T2 publication Critical patent/TR199901855T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bulus genel formül I'in yeni 17alfa-flor alkil steroyidleriyle ilgili olup burada R1 bir metil veya etil grubu, R2 n'in 2,3,4,5 veya 6, m>1 ve m+o=2n+1 oldugu CnFmHo formülünün bir artigi R3 serbest,eterize veya esterize edilmis bir hidroksi grubu, R4 ve R5'ten her biri ayri ayri bir hidrojen atomu, beraber ek bir bilesim veya metilen grubu St kismi formül A, B veya C'nin sterodiyal bir ABC-halka sistemi yerine geçer, burada R6 bir hidrojen atomu, düz zincirli bir C1-C4-veya dalli bir C3-C4-alkil grubu veya bir halojen atomu, R7 bir hidrojen atomu, düz zincirli bir C1-C4-veya dalli bir C3-C4-alkil grubu veya St sterodiyal bir ABC-halka sisteminin A'si veya B'si yerine geçtiginde ayrica R6 ve R7 beraberce ek bir bilesim, X bir oksijen atomu, bir hidroksi imino gruplasmasi =N-OH veya iki hidrojen atomu, R8 bir Y resti veya icabinda çok defa bir Y grubu ile yer degistirmis bir aril resti, Y bir hidrojen atomu, bir halojen atomu, bir -OH,-NO2,-N3,-CN,NR9aR9b, -NHSO2R9, -CO2R9,( DEVAMI VAR)
TR1999/01855T 1997-02-07 1998-02-09 Flore edilmis 17alfa -alkil zincirli antigestajen etkili steroyidler. TR199901855T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19706061A DE19706061A1 (de) 1997-02-07 1997-02-07 Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Publications (1)

Publication Number Publication Date
TR199901855T2 true TR199901855T2 (tr) 2000-04-21

Family

ID=7820508

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01855T TR199901855T2 (tr) 1997-02-07 1998-02-09 Flore edilmis 17alfa -alkil zincirli antigestajen etkili steroyidler.

Country Status (35)

Country Link
US (4) US6316432B1 (tr)
EP (1) EP0970103B1 (tr)
JP (1) JP4324249B2 (tr)
KR (1) KR100511815B1 (tr)
CN (2) CN1246865A (tr)
AR (1) AR010887A1 (tr)
AT (1) ATE216397T1 (tr)
AU (1) AU742834B2 (tr)
BG (1) BG63875B1 (tr)
BR (1) BR9807667A (tr)
CA (1) CA2280041C (tr)
CL (1) CL2004001191A1 (tr)
CZ (1) CZ296328B6 (tr)
DE (2) DE19706061A1 (tr)
DK (1) DK0970103T3 (tr)
EA (1) EA003092B1 (tr)
EE (1) EE03831B1 (tr)
ES (1) ES2175673T3 (tr)
HK (1) HK1040718B (tr)
HU (1) HUP0000968A3 (tr)
ID (1) ID22643A (tr)
IL (1) IL131226A (tr)
IS (1) IS2190B (tr)
MY (1) MY118508A (tr)
NO (1) NO313554B1 (tr)
NZ (1) NZ336989A (tr)
PL (1) PL191808B1 (tr)
PT (1) PT970103E (tr)
SI (1) SI0970103T1 (tr)
SK (1) SK283155B6 (tr)
TR (1) TR199901855T2 (tr)
TW (1) TW499434B (tr)
UA (1) UA66783C2 (tr)
WO (1) WO1998034947A1 (tr)
ZA (1) ZA98985B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EE200300156A (et) * 2000-10-18 2003-08-15 Schering Aktiengesellschaft Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine
US7378406B2 (en) * 2000-10-18 2008-05-27 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
AU2002223619B2 (en) * 2000-10-18 2006-08-24 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
UY26966A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
UY26965A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
DE10051609A1 (de) * 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
ES2290284T3 (es) * 2001-01-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft El uso de antigestagenos para inhibir la maduracion endometrial acelerada durante el tratamiento de infertilidad.
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE307823T1 (de) * 2002-05-03 2005-11-15 Schering Ag 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US7593347B2 (en) * 2003-12-29 2009-09-22 Intel Corporation Method and apparatus to exchange channel information
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
JP2010524997A (ja) * 2007-04-23 2010-07-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｂｒｃａ単独での、又は抗エストロゲン薬を伴った組み合わせ物としての使用のためのプロゲステロン受容体拮抗薬
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
BR112012023281A2 (pt) 2010-03-22 2016-05-17 Repros Therapeutics Inc composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868323A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868321A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for inhibiting autocrine HCG production in adult human cells
HK1245118A1 (zh) 2015-05-18 2018-08-24 Bayer Pharma Aktiengesellschaft 选择性孕酮受体调节剂(sprm)方案
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE310541C (tr) * 1915-12-19 1919-01-30
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
EP0369881A1 (fr) * 1988-11-16 1990-05-23 Roussel-Uclaf Nouveaux produits dérivés de la structure 3-céto delta-4,9 19-nor stéroides et leur application comme médicaments
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
HUP0000968A2 (hu) 2000-10-28
MY118508A (en) 2004-11-30
CN1246865A (zh) 2000-03-08
IS2190B (is) 2007-01-15
HK1040718B (zh) 2005-12-09
UA66783C2 (en) 2004-06-15
TW499434B (en) 2002-08-21
SI0970103T1 (en) 2002-10-31
CA2280041C (en) 2007-10-23
US20030134834A1 (en) 2003-07-17
CL2004001191A1 (es) 2005-03-28
JP2001510479A (ja) 2001-07-31
US20020045774A1 (en) 2002-04-18
HK1040718A1 (en) 2002-06-21
IS5147A (is) 1999-08-04
DK0970103T3 (da) 2002-07-22
KR20000070835A (ko) 2000-11-25
IL131226A (en) 2004-12-15
US20050080060A1 (en) 2005-04-14
DE19706061A1 (de) 1998-08-13
EP0970103B1 (de) 2002-04-17
US6503895B2 (en) 2003-01-07
CN1202120C (zh) 2005-05-18
AR010887A1 (es) 2000-07-12
AU742834B2 (en) 2002-01-10
BG103603A (en) 2000-06-30
PT970103E (pt) 2002-09-30
SK283155B6 (sk) 2003-03-04
CA2280041A1 (en) 1998-08-13
AU6100598A (en) 1998-08-26
BR9807667A (pt) 2000-02-15
KR100511815B1 (ko) 2005-09-05
CN1324802A (zh) 2001-12-05
US6316432B1 (en) 2001-11-13
ZA98985B (en) 1999-08-03
EE9900339A (et) 2000-02-15
NZ336989A (en) 2001-04-27
NO993811D0 (no) 1999-08-06
CZ280599A3 (cs) 2000-01-12
ID22643A (id) 1999-12-02
EE03831B1 (et) 2002-08-15
NO313554B1 (no) 2002-10-21
CZ296328B6 (cs) 2006-02-15
SK103899A3 (en) 2000-05-16
US6806263B2 (en) 2004-10-19
EA003092B1 (ru) 2002-12-26
DE59803856D1 (de) 2002-05-23
HUP0000968A3 (en) 2001-03-28
EP0970103A1 (de) 2000-01-12
WO1998034947A1 (de) 1998-08-13
PL191808B1 (pl) 2006-07-31
BG63875B1 (bg) 2003-04-30
EA199900644A1 (ru) 2000-04-24
JP4324249B2 (ja) 2009-09-02
PL334878A1 (en) 2000-03-27
IL131226A0 (en) 2001-01-28
ATE216397T1 (de) 2002-05-15
US7148213B2 (en) 2006-12-12
NO993811L (no) 1999-10-04
ES2175673T3 (es) 2002-11-16

Similar Documents

Publication Publication Date Title
DK1075260T3 (da) Hidtil ukendte fedtsyreanaloger til behandling af sekundær restenose
TR199700642A2 (tr) Organosilanpolisülfanlarin karisimi ve bu karisimlari ihtiva eden kauçuk bilesimleri üretmeye mahsus yöntem.
ES2192067T3 (es) Esteres con olor almizclado y su utilizacion en perfumeria.
DK0495053T3 (da) Ny linker til bioaktive midler
TR199901874T2 (tr) 3'-n-oksit,3'-n-dimetilamin, 9-oksim eritromisin A türevleri.
BR9809474A (pt) Policarbonatos baseados em silìcio
TR199801399T2 (tr) Yeni 19-nor-pregnen türevleri.
BR9906440A (pt) Agentes de tingimento de oxidação contendo derivados de 2,5-diamino-1-fenilbenzeno bem como derivados de 2,5-diamino-1-fenilbenzeno
TR200002009T2 (tr) Yeni aromatik amidler, hazırlama yöntemi ve ilaç olarak kullanılması.
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
KR960014137A (ko) 새로운 선스크린제들, 그것을 함유하는 광보호성 화장용 조성물과 그 용도
ATE226210T1 (de) Phospholipidanaloge verbindungen
MX9705309A (es) Analogos de n-acetilardeemina, metodo de preparacion y sus usos.
BR0012830A (pt) Silanos fenólicos bloqueados
ES2134732B1 (es) "mezclas estabilizantes".
ATE290029T1 (de) Polysiloxan und textilhilfsmittel enthaltend ein polysiloxan
WO2002009662A3 (de) Mittel zum färben von keratinhaltigen fasern
TR199700802T2 (tr) Triazin türevleri.
NO953163D0 (no) Aziridinoantracyklinderivater
PE20020472A1 (es) Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales
ATE345335T1 (de) Acetale, ihre verwendung als riechstoffe und verfahren zu ihrer herstellung
TR199802555T2 (tr) Bir riboz ile ornatilmis yeni aromatik türevler.
ES2157322T3 (es) Composicion de cemento.
PL341837A1 (en) Novel tricyclic compounds, method of obtaining them and pharmacological compositions containing such compounds
TR200002803T2 (tr) MRP1 inhibe etmek için yöntemler.